Home » Stocks » DMAC

DiaMedica Therapeutics Inc. (DMAC)

Stock Price: $8.42 USD -0.89 (-9.56%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $8.40 -0.02 (-0.24%) Jan 26, 7:54 PM
Market Cap 157.78M
Revenue (ttm) n/a
Net Income (ttm) -10.57M
Shares Out 16.69M
EPS (ttm) -0.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $8.42
Previous Close $9.31
Change ($) -0.89
Change (%) -9.56%
Day's Open 8.92
Day's Range 8.25 - 9.00
Day's Volume 259,315
52-Week Range 2.25 - 10.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 2 weeks ago

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today ann...

Business Wire - 1 month ago

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that the last participant has been enrolled and is on treatment in the diabetic kidney disease Cohort o...

Business Wire - 1 month ago

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that it recently received written responses from the FDA following a Type B Pre-IND meeting request that the ...

Business Wire - 2 months ago

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neur...

Business Wire - 2 months ago

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for chronic kidney diseases and neurological di...

Seeking Alpha - 2 months ago

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological...

Business Wire - 2 months ago

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its third quarter 2020 financial results will be released after the markets close on Wednesday, No...

Business Wire - 4 months ago

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, has been invited to present at Lake Street’s 4th Annual Best Ideas Growth (BIG...

Business Wire - 4 months ago

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for chronic kidney disease, today announced dos...

Seeking Alpha - 5 months ago

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2020 Results - Earnings Call Transcript

Business Wire - 5 months ago

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological...

Business Wire - 5 months ago

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the closing of its previously announced underwritten registere...

Business Wire - 5 months ago

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2020 financial results will be released after the markets close on Tuesday, Aug...

Business Wire - 5 months ago

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the pricing of the previously announced underwritten registere...

Business Wire - 5 months ago

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today that it intends to offer and sell its common shares in an unde...

Benzinga - 6 months ago

DiaMedica Therapeutics (NASDAQ: DMAC) shares are trading higher on Wednesday after Maxim Group initiated coverage on the stock with a Buy rating and announced a price target of $14 per share.

Seeking Alpha - 8 months ago

DiaMedica Therapeutics Inc.'s (DMAC) CEO Rick Pauls on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 10 months ago

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

MINNEAPOLIS, Sept. 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will attend the Lake Street Capital Markets 3rd Annual Best Ideas G...

GlobeNewsWire - 1 year ago

MINNEAPOLIS, Sept. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will present at the 2019 Dougherty & Co. Institutional Investor Con...

Seeking Alpha - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2019 Results - Earnings Call Transcript

Benzinga - 1 year ago

Shares of the thinly traded nano-cap biotech DiaMedica Therapeutics Inc (NASDAQ: DMAC) were rallying strongly Thursday.

Seeking Alpha - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2018 Results - Earnings Call Transcript

About DMAC

DiaMedica Therapeutics, a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company also develops ... [Read more...]

Industry
Biotechnology
Founded
2000
CEO
Dietrich John Pauls M.B.A., MBA
Employees
8
Stock Exchange
NASDAQ
Ticker Symbol
DMAC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for DMAC stock is "Strong Buy." The 12-month stock price forecast is 16.20, which is an increase of 92.40% from the latest price.

Price Target
$16.20
(92.40% upside)
Analyst Consensus: Strong Buy